Navigation Links
BioDelivery Sciences Announces Results from Phase 3 Efficacy Study for BEMA Buprenorphine in Chronic Pain
Date:9/28/2011

BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL is registered trademark of Meda Pharma GmbH & Co. KG.

Cautionary Note on Forward-Looking Statements

This press release, the presentation described herein and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, those relating to the future clinical and commercial development of BEMA Buprenorphine) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publically update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.  

Readers are cautioned that peak sales and market size estimates have been deter
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
5. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
6. Derma Sciences Reports Second Quarter 2008 Results
7. Advanced Life Sciences Announces Second Quarter 2008 Financial Results
8. The Michigan Life Sciences Pipeline Adds More Resources On Its Website
9. Milestone Biosciences, LLC Further Strengthens Executive Management Team
10. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
11. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Convey Computer , ... team from Iowa State University won first place in ... a Convey HC-2ex, the team’s solution achieved the highest ... than the second place finisher. , Experts from all ... the month long challenge, using a variety of design ...
(Date:10/20/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... orders to $5.8 million and provides a good start to Q4.  ... North America and one in the Middle ... at record levels," said Peter Bruijns , President & CEO. ... of Q3 than they have been for any complete year since ...
(Date:10/20/2014)... 20, 2014  GenVec, Inc. (NASDAQ: GNVC ) ... Ph.D., from its board of directors effective on October 24, ... and served as its chairman from June 2006 to November ... and Corporate Governance and Audit Committees of the board.  ... decade of dedicated service to GenVec, and its stockholders," said ...
(Date:10/20/2014)... PLAINSBORO, N.J. (PRWEB) October 20, 2014 ... that the Sidney Kimmel Cancer Center at Thomas ... program. , Through the Strategic Alliance Partnership ... and OncLive will collaborate to raise awareness of ... cancer treatment, and other projects. Clinicians and other ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... Initiated To Support Ongoing ... Trials-, -Clinical Data Expected in ... in Major Disease Indications-, -Revenues Plus Cash On-Hand Expected to Provide Sufficient Resources ... Advance Programs as Planned-, TUSTIN, ...
... Hosts Three Customer Audits, Continues Growth Strategy ... Industry-Leading Software Tools, MOUNTAIN VIEW, Calif., Dec. ... leading provider of software, strategic,consulting, and regulatory services ... global biopharmaceutical companies,have performed audits of its Reporting ...
... Md., Dec. 20 Human Genome,Sciences, Inc. (Nasdaq: ... sponsor a,conference call to discuss its licensing and ... the initiation of a second randomized,Phase 2 trial ... http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ), This conference call ...
Cached Biology Technology:Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 2Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 3Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 4Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 5Pharsight's Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2Pharsight's Reporting and Analysis Services Business Reaches Quality Assurance Milestone 3Pharsight's Reporting and Analysis Services Business Reaches Quality Assurance Milestone 4Human Genome Sciences to Sponsor Conference Call 2
(Date:10/17/2014)... German . To ... treating overdoses, doctors are often limited to supportive therapy such ... a combination of drugs involved. So what can be done ... pills? ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical ... this question. "The task was to develop an agent that ...
(Date:10/16/2014)... can be cultivated efficiently, they are anything but ... by monoculture cultivation is becoming increasingly evident. Despite ... form and are regarded as the sole possibility ... quite wrongfully, finds Bernhard Schmid, an ecology professor ... novel form of agriculture and forestry. After all, ...
(Date:10/15/2014)... our ability to assess the pandemic risk from strains ... we must not allow ourselves to become complacent that ... international consortium of scientists. , Influenza pandemics arise when ... yet to develop widespread immunity – spreads in the ... the past 100 years, the worst of which – ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... STAMFORD, Conn., July 30 L-1 Identity,Solutions, Inc., ... identity solutions and,services, will hold a supplemental conference ... quarter and six months ended June 30,2008 financial ... technical,difficulties, conference participants in the initial 11:00 a.m. ...
... field trial of its kind in the United States, ... x giganteus outperforms current biofuels sources by a ... in the U.S. could significantly reduce the acreage dedicated ... researchers report. The new findings, from researchers at ...
... is one of the most serious mental illnesses and ... affect. Environmental as well as genetic factors form a ... published in the Internet editions of the professional journals ... offered a ground-breaking step in the complex and extraordinarily ...
Cached Biology News:L-1 Identity Solutions to Hold Supplemental Second Quarter 2008 Financial Results Q&A Conference Call at 2:00p.m. (ET) Today 2Miscanthus can meet US biofuels goal using less land than corn or switchgrass 2Miscanthus can meet US biofuels goal using less land than corn or switchgrass 3Advances in the field of schizophrenia research: New genetic factors identified 2Advances in the field of schizophrenia research: New genetic factors identified 3
8.1.1...
... and efficient purification of DNA and oligonucleotides ... by gravity flow.Prepacked with Sephadex G-25 DNA ... CG/ICP Biocide.Available in three sizes depending on ... ml (NAP-10) or 2.5 ml (NAP-25).Useful for ...
Human Serpin A3 MAb (Clone 213907)...
Human DC-SIGNR/CD209L MAb (Clone 120604)...
Biology Products: